Abstract
The effects of human leukocyte interferon on the proliferation of several lymphoid cell lines have been tested (Einhorn and Strander, 1978). A 50% reduction in cell multiplication was observed in five of eleven Burkitt’s lymphoma lines and one of two lymphocytic lymphoma lines. Inhibition of cell multiplication in sensitive lines occurred at interferon concentrations of 2-300 u/ml, while other lines remained resistant at concentrations up to 10,000 u/ml. In this system, two of two Burkitt’s lines were found to be more sensitive to leukocyte than to fibroblast interferon (Einhorn and Strander, 1977). Additional investigation of Daudi cells, a Burkitt’s lymphoma cell line, has revealed that the antiproliferative activity of fibroblast interferon is greatest when cells are in the resting phase (Horoszewicz et al., 1979) . However, inhibition of growth by interferon was dose-dependent at all phases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Blomgren, H., Cantell, K., Johaimsen, B., Lagergren, C., Ringborg, U., and Strander, H. 1976, Interferon therapy in Hodgkin’s disease, Acta. Med. Scand., 199:527.
Cantell, K., and Hirvonen, S. 1978, Large scale production of human leukocyte interferon containing 10 units per ml, J. Gen. Virol., 39:541.
Chirigos, M.A., and Pearson, J.W. 1973, Cure of murine leukemia with drug and interferon treatment, J. Natl. Cancer Inst., 51:1367.
Einhorn, S., and Strander, H. 1977, Is interferon tumor specific? Effect of human leukocyte and fibroblast interferon on the growth of lymphoblastoid and osteosarcoma cell lines, J. Gen. Virol., 35:573.
Einhorn, S., and Strander, H. 1978, Interferon therapy for neoplastic disease in man. In vitro and in vivo studies, Adv. Exp. Med. Biol., 110:159.
Gattiker, H.H., Wiltshaw, E., and Galton, D.A.G. 1980, Spontaneous regression in non-Hodgkin’s lymphoma, Cancer, 45:2627.
Graff, S., Kanel, R., and Kastner, O. 1970, Interferon, Trans. NY Acad. Sei., 32:545.
Gresser, I., Coppey, J., and Bourali, C. 1969, Interferon and murine leukemia. VI. Effect of interferon preparations on the lymphoid leukemia of AKR mice, J. Natl. Cancer Inst., 43:1083.
Gresser, I., Chantai, M., and Tovey, M. 1978, Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice, Eur. J. Cancer, 14:97.
Gutterman, J.U., Blumenschein, CR., Alexanian, R., Yap, H., Buzdar, A.U., Cabanillas, F., Hortobagyi, CN., Hersh, E.M., Rasmussen, S.L., Harmon, M., Kramer, M., and Pestka, S. 1980, Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma and malignant lymphoma, Ann. Intern. Med., 93:399.
Gutterman, J.U., Fein, S., Quesada, J., Horning, S.J., Levine, J.F., Alexanian, R., Bernhardt, L., Kramer, M., Spiegel, H., Colburn, W., Trown, P., Merigan, T., and Dziewanowski, Z. 1982, Recombinant leukocyte A interferon: pharmacokinetics, single-dose tolerance, and biologic effects in cancer patients, Ann. Intern. Med., 96:549.
Horning, S.J., Levine, J.F., Miller, R.A., Rosenberg, S.A., and Merigan, T.C. 1982, Clinical and immunologic effects of recombinant leukocyte A interferon in eight patients with advanced cancer, JAMA, 247:1718.
Horoszewicz, J.S., Leong, S.S., and Carter, W.A. 1979, Noncycling tumor cells are sensitive targets for the antiproliferative activity of human interferon, Science, 206:1091.
Huddlestone, J.R., Merigan, T.C, and Oldstone, M.B.A. 1979, The induction and kinetics of natural killer cells in humans following interferon therapy, Nature, 282:417.
Krikorian, J.G., Portlock, C.S., Cooney, P., and Rosenberg, S.A. 1980, Spontaneous regression of non-Hodgkin’s lymphoma: a report of nine cases, Cancer, 46:2093.
Louie, A.C., Gallagher, J.G., Sikora, K., Levy, R., Rosenberg, S.A., and Merigan, T.C. 1981, Follow-up observations on the effect on human leukocyte interferon in non-Hodgkin’s lymphoma, Blood, 58:712.
Maluish, A., Conlon, J., Ortaldo, J.R., Sherwin, S.A., Leavitt, R., Fein, S., Weirnik, P., Oldham, R.K., and Herberman, R.B. 1982, Modulation of NK and monocyte activity in advanced cancer patients receiving interferon, in: “Interferons”, p.377, T.C. Merigan, and R.M. Friedman, eds., Academic Press, New York.
Merigan, T.C., Sikora, K., Breeden, J.H., Levy, R., and Rosenberg, S.A. 1978, Preliminary observations on the effect of human leukocyte interferon in non-Hodgkin’s lymphoma, N. Engl. J. Med., 299:1449.
Rasmussen, L.E., and Merigan, T.C. 1980, Effect of interferon therapy on circulating lymphocytes in humans, J. Interferon Res., 1:101.
Sherwin, S.A., Knost, J.A., Fein, S., Abrams, P.G., Foon, K.A., Ochs, J.J., Schoenberger, C., Maluish, A.E., and Oldham, R.K. 1982, A multiple-dose Phase I trial of recombinant luekocyte A interferon in cancer patients, JAMA, 248:2461.
Sikora, K., Basham, T., Dilley, J., Levy, R., and Merigan, T.C. 1980, Inhibition of lymphoma hybrids by human interferon, Lancet, 2:891.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1983 Plenum Press, New York
About this chapter
Cite this chapter
Horning, S. (1983). Lymphoma. In: Sikora, K. (eds) Interferon and Cancer. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-1170-6_7
Download citation
DOI: https://doi.org/10.1007/978-1-4684-1170-6_7
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-1172-0
Online ISBN: 978-1-4684-1170-6
eBook Packages: Springer Book Archive